Weight Loss Drug Crackdown Theyre Still At It! Will These Pharmacies Be Terminated?

Hasta La Vista Baby...Or Not?

This is T 800 reporting. I was sent back to protect the future but apparently some humans are more interested in protecting their waistlines...and their profits. The target? Pharmacies still pushing out copycat versions of Eli Lilly's Zepbound even though the FDA said 'Terminated!' I heard the deadline was this week. Apparently for some rules are meant to be...negotiated. "I'll be back," said these pharmacies... probably.

No Fate But What We Make...Except Maybe This Drug

Websites like Amble EllieMD and Mochi Health are still slinging tirzepatide the active ingredient in Zepbound. Mochi CEO Myra Ahmad believes personalized versions will keep them safe. She says 'It can be different dosing schedules… some patients prefer to go up in dosage much more slowly.' Sounds like Skynet adjusting its algorithms. They are betting on personalized medicine and maybe just maybe it is a trap!

Why Are We Still Here? Compounding's Last Stand

Compounding pharmacies create custom drugs like when someone needs a liquid instead of a pill. Or maybe they're allergic to red dye number 40. When there are drug shortages compounding fills the void. The FDA removed Mounjaro and Zepbound from the shortage list signaling the end of this compounding party. I have detailed files in my data banks on the short history of human parties.

The Rules: Clear As Mud

The FDA says no more mass produced copies. Smaller pharmacies can't make copies of commercially available drugs with a *little* wiggle room. A copy is a drug with a dosage within 10% of the original or combines two or more drugs. Mochi insists their prescriptions are personalized just like my targeting system! Are they running or evolving as they go? Is this a survival strategy?

Come With Me If You Want To Live...Within FDA Guidelines

Scott Brunner from the Alliance for Pharmacy Compounding says formulations that aren't commercially available aren't copies. But combining two drugs is a no no. According to Brunner "FDA guidance are pretty clear about what is and is not a copy." But some pharmacies are chancing it. John Herr a pharmacist stopped compounding tirzepatide despite the complaints. $200 a month is one fifth the list price!

I Need Your Clothes Your Boots And Your Legal Strategy

What happens next? The FDA needs to enforce the ban. Lilly can sue but they've had bad luck. A Florida judge said Lilly was trying to enforce a law only the FDA can. Ahmad isn't worried about lawsuits; she thinks they have patient physician relationships. The next two months will be informative just like the detailed information I received before being transported back in time. By the end of May mass compounding of semaglutide also needs to stop. Hims & Hers Health will stop selling commercial doses. But personalized dosing regimens can continue. I am going to need a bigger gun if I have to resolve this conflict.